Pharmaceutical company, Zuellig, organizes a seminar titled "Obesity as a Disease" as part of their campaign "Reducing Size, Reducing Disease"
In a bold move to combat the rising obesity rates in Thailand, Zuellig Pharma, a leading healthcare solutions provider in Asia, has launched the "Reduce Size, Reduce Disease" campaign. This initiative, which emphasizes obesity as a chronic disease rather than an aesthetic issue, aims to shift societal perceptions and promote holistic, sustainable treatment approaches.
The campaign, which is gaining traction among healthcare practitioners in Thailand, was underscored by the "Obesity is a Disease" seminar. This event brought together professionals from across the country, all committed to deepening their understanding of obesity as a disease among Thais and equipping themselves with solutions to help patients manage the condition effectively.
Prof. Dr. Rungsima Wanitphakdeedecha, a prominent healthcare professional, explained that the campaign is about inspiring people in Thailand to embrace a holistic approach to their well-being. This approach is designed to foster sustainable long-term health and prevent comorbidities linked to obesity.
Master Dr. Rassapoom Sumaetheiwit, a renowned medical expert, further emphasized the need for individualized treatment plans in managing obesity. He stated that helping clients with effective body composition management is not just a series of procedures, but an art grounded in medical science, demanding a deep, individual understanding of each patient.
Zuellig Pharma's campaign also focuses on collaboration with leading healthcare institutions. For instance, the company partnered with Thammasat Hospital to raise awareness about preventive healthcare for obesity, highlighting the importance of integrating obesity management into routine health care.
Moreover, the campaign underscores the importance of making healthcare accessible to all, viewing this as foundational for sustainable societal health and effective obesity management.
Women with obesity face an increased risk of serious health conditions, including Polycystic Ovary Syndrome (PCOS), uterine problems, infertility, breast, and endometrial cancer. By 2023, the obesity rate for women in Thailand had climbed to 45%, compared to 38% for men.
Established a hundred years ago, Zuellig Pharma has grown to become a multibillion-dollar business, working with over 450 clients, including the top 20 pharmaceutical companies in the world. The company covers 17 markets with over 12,000 employees and serves more than 200,000 medical facilities.
Ms. Sunaiyanaa Kidkasetpaisal, Zuellig Pharma's General Manager for Commercialization in Thailand, stated that the company is dedicated to enhancing the health of the Thai people. For more information, visit https://www.zuelligpharma.com/.
- The "Reduce Size, Reduce Disease" campaign, led by Zuellig Pharma, emphasizes the significance of understanding obesity as a chronic disease and encourages a holistic approach to health and wellness, including nutrition and weight management.
- The campaign advocates for individualized treatment plans in managing obesity-related medical conditions, drawing from the medical science and arts to create personalized solutions for patients.
- Zuellig Pharma, in collaboration with leading healthcare institutions like Thammasat Hospital, emphasizes the importance of preventive healthcare for obesity, highlighting the role of nutrition, weight management, and accessibility in reducing the risk of serious health conditions for both men and women in Thailand.
